To include your compound in the COVID-19 Resource Center, submit it here.

Quizartinib: Interim Phase II data

An ongoing, open-label, international Phase II trial in 53 evaluable patients showed that once-daily oral AC220 produced a CRc rate of 45% within the

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE